A
Alcista
Alcista · 25%HKPD
$1.53
Precio del escenario
$1.450
+0.096 (+6.62%)Al cierre
Loading chart…
- Máximo
- 1.600
- Apertura
- 1.420
- Precio medio ponderado por volumen
- 1.47
- Volumen
- 48.81K
- Capitalización
- —
- Mínimo
- 1.360
- Importe
- 71.76K
- EV/EBITDA, TTM
- 0.00
Cellyan Biotechnology Co Ltd is an investment holding company mainly engaged in the over the counter (OTC) pharmaceutical business. The Company mainly provides two services. The supply chain services mainly provide OTC pharmaceutical cross-border e-commerce supply chain services. The procurement and distribution services mainly provide OTC pharmaceutical cross-border procurement and distribution services.
Análisis de IA of Cellyan Biotechnology Co Ltd (HKPD)
VenderGiven the current price of 1.45, the RSI at 25.446 indicates that the stock is oversold, but the significant year-to-date decline of 91.01% and negative earnings trends suggest that this is not a good buy right now. The main risk is the compliance warning from Nasdaq, which could further impact investor confidence and stock performance.
Métricas de valoración
El PER previsto actual de Cellyan Biotechnology Co Ltd (HKPD) es 0.00, frente a su media de 5 años de 0.00.
Escenarios de precio de Alphio AI para HKPD
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Cronología de eventos
Noticias
7.007-17NASDAQ.COMCellyan Biotechnology Receives Nasdaq Compliance Extension
8.507-16seekingalphaCellyan Biotechnology Secures Nasdaq Compliance Extension
- 8.501-16seekingalpha
Cellyan Biotechnology (HKPD) Receives Nasdaq Warning for Non-Compliance with $1 Minimum Bid Price
7.001-16GlobenewswireCellyan Biotechnology Receives Nasdaq Notification for Share Price Below $1
- 9.012-17Globenewswire
HKPD Approves Major Capital Restructuring at 2025 Annual Meeting
Preguntas frecuentes sobre HKPD, respondidas por Alphio AI
Cellyan Biotechnology Co Ltd is an investment holding company mainly engaged in the over the counter (OTC) pharmaceutical business. The Company mainly provides two services. The supply chain services mainly provide OTC pharmaceutical cross-border e-commerce supply chain services. The procurement and distribution services mainly provide OTC pharmaceutical cross-border procurement and distribution services. It operates in the Healthcare sector.
Given the current price of 1.45, the RSI at 25.446 indicates that the stock is oversold, but the significant year-to-date decline of 91.01% and negative earnings trends suggest that this is not a good buy right now. The main risk is the compliance warning from Nasdaq, which could further impact investor confidence and stock performance.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarArtículos relacionados
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.